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ABSTRACT
The restoration of blood flow to ischemic cerebral tissue after recombinant tissue
plasminogen activator and/or mechanical thrombectomy can result in reperfusion injury, and
the contribution of reperfusion injury to the total tissue damage can amount to at least 50%.
Therefore, blocking reperfusion injury during restoration of blood flow following ischemic
stroke can significantly aid in recovery of ischemic tissue. The peptide hormone bradykinin has
previously been shown in many studies to exhibit protective effects when released from the
surrounding vascular endothelium. However, during reperfusion, bradykinin does not reach
protective levels due to its rapid inactivation by aminopeptidase P2 (APP2) and angiotensin
converting enzyme. Therefore, inhibiting APP2 during restoration of blood flow is a potential
therapeutic strategy to aid in the reduction of reperfusion injury, and thus led to the
development of the highly potent and very specific APP2 inhibitor, ST-115. It was hypothesized
that administration of ST-115 during ischemic stroke, and just prior to reperfusion, will result in
reduced neurological injury and increased functional recovery in a rat model of transient middle
cerebral artery occlusion. Here, we report that inhibition of APP2 with ST-115 treatment five
minutes prior to reperfusion reduces edema and inflammation and promotes functional
recovery post stroke. Given the role reperfusion injury plays in total stroke damage, this data
suggests that inhibition of APP2 may be a viable pharmaceutical target for improving stroke
outcomes.
xi

CHAPTER ONE
OVERVIEW AND HYPOTHESIS
Overview
Cerebrovascular accidents (stroke) are the fifth leading cause of death and a leading cause
of disability worldwide. Greater than 80% of strokes are classified as ischemic stroke. Ischemic
stroke occurs after occlusion of a cerebral blood vessel, most commonly the middle cerebral
artery or one of its branches, and results in the rapid decline of focal neurological function and
brain death [10, 33, 87]. When occlusion of a cerebral blood vessel occurs, nutrients can no
longer be provided to cells due to lack of blood flow, ceasing aerobic metabolic activity [50].
The resulting reduction in ATP production and decrease in intracellular pH impair ATPasedependent ion transport [59]. As a consequence, calcium influx is increased and calcium efflux
is reduced, leading to cellular calcium overload, mitochondrial dysfunction, and possible
apoptosis or necrosis [47].
Currently, the only FDA approved treatment for acute ischemic stroke is recombinant tissue
plasminogen activator (rtPA), a serine protease that catalyzes the cleavage of plasminogen to
plasmin, a major enzyme responsible for the breakdown of thrombi. However, in multiple
clinical trials, rtPA has only been shown to be effective if administered within the early hours
after the onset of stroke-induced symptoms [18, 23, 44, 95]. In addition, regardless of rtPA
therapy, most stroke patients will undergo mechanical thrombectomy, the endovascular
1
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procedure of removing a blood clot from the cerebral arteries. According to the American
Stroke Association, mechanical thrombectomy in addition to rtPA administration is now the
recommended treatment for ischemic stroke [76]. Despite apparent success in both treatment
methods, especially in combination, they exacerbate what is termed “reperfusion injury.” Once
thought to recover previously ischemic tissue, it is now understood that the rapid reperfusion
of ischemic tissues exacerbates tissue damage due to ischemia. The rapid restoration of blood
flow leads to an influx of oxygen to ischemic tissues, and therefore aids in the accelerated
production of xanthine oxidase-driven reactive oxygen species (ROS). Furthermore, during
reperfusion, accumulated extracellular hydrogen ions are “washed out.” This removal of
hydrogen ions restores extracellular pH, leading to additional calcium influx and worsening the
intracellular calcium overload already sustained during ischemia [47].
Additionally, the increased ROS, in combination with activated proinflammatory cytokines
produced during ischemia and reperfusion, activate matrix metalloproteinases (MMPs).
Activation of MMPs results in degradation of the extracellular matrix and tight junctions in
endothelial cells, eventually leading to disruption of the blood brain barrier (BBB) and apoptosis
of glial and endothelial cells. In addition to hemorrhage, disruption of the BBB leads to the
additional influx of proinflammatory immunocytes into the brain, resulting in worsened
inflammation near the damaged tissue. While neuronal inflammation leads to multiple
deleterious effects, one of particular importance is the development of a no-reflow
phenomenon. Neuronal and capillary endothelial cell inflammation result in the reduction of
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capillary luminal diameter, establishing a capillary no-reflow phenomenon that worsens during
reperfusion and heightens tissue injury. During reperfusion, ROS generation, worsened
intracellular calcium overload, and the various inflammatory responses lead to the opening of
mitochondrial permeability transition pores (MPTP). In combination with activated MMPs and
the capillary no-reflow phenomenon, MPTPs lead to ischemia and reperfusion-induced cell lysis
and eventually cell death [47].
As the duration of an ischemic stroke lengthens, reversible injury to tissues worsens to
irreversible injury. The area of irreversible injury is termed the core, while the area of reversible
injury is termed the penumbra. In the early hours of ischemia, the ischemic core is surrounded
by an area of ischemic penumbra. However, as the stroke progresses, the diameter of the core
increases and the penumbra decreases, eventually leaving only irreversible tissue damage. It is
thought that reperfusion injury worsens this progression, and therefore, salvaging the tissue in
the penumbra is a viable and urgent target of therapeutic intervention following ischemic
stroke [7, 65].
One area of therapeutic interest is the action of the hormone bradykinin. While bradykinin
plays an extensive amount of roles in the body, it is thought to be a critical inflammatory
mediator in the central nervous system. When bradykinin binds to its B2 receptor on the
luminal surface of vascular endothelial cells it induces the release of low levels of nitric oxide
(NO) and prostacyclin (PGI2), blocking necrosis and apoptosis by inhibiting MPTP formation, and
mediating inflammation. Bradykinin is produced by vascular endothelial cells, including during
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ischemia and reperfusion [4, 24, 46, 78, 81, 82]. However, endogenous levels of bradykinin do
not reach sufficient levels to protect against ischemic and reperfusion injury, and this is in part
due to its inactivation by aminopeptidase P2 (APP2), an enzyme that acts inactivates bradykinin
[58, 85].
Dr. Simmons’s lab has developed the APP2 inhibitor ST-115 to reduce reperfusion injury
following ischemic stroke. Inhibition of APP2 just prior to reperfusion leads to an indirect
elevation in bradykinin levels, which act on the B2 receptor to block reperfusion injury. ST-115
has previously been shown to reduce reperfusion injury-associated tissue damage in animal
models of myocardial infarction and kidney injury. However, ST-115’s potential role in ischemic
stroke recovery is also critical, due to the unmet need for a drug that successfully and
substantially reduces brain damage secondary to ischemic stroke. Furthermore, ST-115 is
compatible with current treatments, as it could be administered in combination with rtPA and
mechanical thrombectomy.
Hypothesis
It is hypothesized that administration of ST-115 during ischemic stroke, and five minutes
prior to reperfusion, will result in reduced neurological injury and increased functional recovery
in a rat model of transient middle cerebral artery occlusion.
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Specific Aims
Specific Aim 1
Determine if ST-115 treatment results in improved functional recovery following
cerebral ischemia and reperfusion in a rat transient middle cerebral artery occlusion model.
Short-term functional recovery will be quantified via the horizontal ladder rung walk at 24
hours post-reperfusion, and compared to baseline. Long-term functional recovery will be
quantified via the horizontal ladder rung walk at 24 hours, 2 weeks, and 6 weeks postreperfusion, and compared to baseline.
Specific Aim 2
Determine if ST-115 treatment results in reduced neurological injury following cerebral
ischemia and reperfusion in a rat transient middle cerebral artery occlusion model. Short -term
neurological injury will be quantified at 24 hours post-reperfusion via infarct volume and brain
edema analysis. Long-term neurological injury will be quantified at 6-week survival postreperfusion via infarct volume and immunohistochemical analyses.

CHAPTER TWO
REVIEW OF LITERATURE
Epidemiology of Ischemic Stroke
2.9% of Americans report having suffered a stroke in their lifetime, and an average of
795,000 people experience a new or recurrent stroke each year. In the United States, stroke is
the fifth leading cause of mortality, responsible for every 1 in 19 deaths. Stroke is also a leading
cause of serious long-term disability [10]. According to the Centers for Disease Control and
United States Census Bureau, 2.4% of Americans reported disability secondary to stroke [13].
Common short-term complications due to stroke include seizures, deep vein thrombosis, and
pulmonary embolism; common long-term disabilities include depression, anxiety, cognitive
impairment, dementia, gait instability, and epilepsy [10]. Additionally, stroke has been found to
worsen age-related cognitive and functional decline [27].
Of all strokes suffered in the U.S., 87% are classified as ischemic [10]. A stroke is
considered ischemic when a cerebral blood vessel is occluded, most commonly by large-artery
atherosclerosis, cardiogenic embolism, or small vessel diseases. The middle cerebral artery
(MCA) is the largest cerebral artery, and the most common vessel occluded during ischemic
stroke, accounting for 70% of infarcts [33, 87]. The MCA directly branches from the internal
carotid artery, and further branches into four segments, M1-M4. Cortical targets of the MCA
6
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segments include the primary motor cortex, responsible for skilled motor movements in both
humans and rodents [69].
Mechanisms Underlying Ischemia
Energy Depletion
When ischemic stroke occurs, the lack of blood flow halts nutrient delivery to affected
cells, most notably glucose and oxygen (hypoxia). The result is disruption of oxidative
phosphorylation, and therefore mitochondrial dysfunction and a significant reduction in ATP
production. The brain is especially susceptible to reduction in aerobic metabolism due to its
significantly low levels of glycogen stores and high levels of metabolic activity under normal
physiological conditions. In order to account for the reduction in ATP during standard hypoxia,
the brain uses multiple backup mechanisms to produce ATP. The first is that of creatine kinase
to produce ATP from phosphocreatine, ADP, and H+. However, during ischemia,
phosphocreatine levels are also reduced [51]. In a study on adult rats undergoing ischemia,
phosphocreatine levels were shown to reduce to 30% of their baseline values, compared to
only a 10% reduction of ATP [30]. This leads to a shift in equilibrium and further utilization of
ATP. Furthermore, the brain also uses the action of adenylate cyclase to produce AMP and ATP
from two ADP. During the onset of ischemia, however, there is a significant breakdown in ATP
to AMP for utilization of energy, shifting to increased production of ADP in this adenylate
cyclase pathway [51]. Under ischemic conditions, cessation of nutrient delivery results in a
significant reduction in ATP.
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Acidosis
Phosphofructokinase, an enzyme that phosphorylates fructose-6-phosphate and the key
regulatory step of glycolysis, is allosterically inhibited by ATP and phosphocreatine, and
activated by ADP and AMP [83]. The significant reduction of ATP at the onset of ischemic
conditions activates phosphofructokinase, and therefore drives the glycolytic pathway to
produce two pyruvate and two NADH molecules. Due to the disruption of oxidative
phosphorylation brought on by hypoxia secondary to ischemia, the glycolytic products drive the
lactate dehydrogenase reaction, producing lactate and eventually inducing lactic acidosis [50].
While lactate is produced primarily in astrocytes, it is also released and taken up by neurons,
ultimately reducing pH levels in both cell types [59].
Excitotoxicity
Under normal physiological conditions, the Na+/H+ exchanger (NHE) on cell membranes
plays a vital role in stabilizing intracellular pH in multiple central nervous system cell types. In
order to accommodate for the reduction in intracellular pH during the first moments of
ischemia, the NHE extrudes H+ ions down their concentration gradient in exchange for Na + ions
[91]. However, accumulating Na+ ions cannot be exported from the cell due to the rapid
depletion in ATP. The majority of ATP stores in the brain are used to maintain ion homeostasis
via membrane-bound ATPases, and reduction of ATP is strongly linked to disruptions of ion
gradients across plasma membranes [38, 51]. The Na+/K+ ATPase consumes two-thirds of the
brain’s ATP stores, and as a result is greatly affected by the reduced ATP levels during ischemia.
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Failure of the Na+/K+ pump within the first few minutes of ischemia, coupled with the activation
of NHE, leads to increased concentration of Na + ions inside the cell. The rapid influx of Na+ ions
drives the collapse of membrane potential, stimulating influx of Ca 2+ through voltage-gated Ca2+
channels, further depolarizing the membrane and triggering the release of glutamate stored in
presynaptic vesicles. Released glutamate then activates the opening of NMDA receptors on the
postsynaptic membrane, facilitating additional Ca2+ influx inside cells [41, 88]. Furthermore,
disruption of the Na+ ionic gradient reverses reuptake, driving a surge of glutamate in the
synaptic cleft and uncontrolled Ca2+ influx, worsened by failure of ATPases on cell and
sarco/endoplasmic membranes responsible for removal of cytoplasmic Ca 2+. As a result, cells
experience excitotoxicity within minutes of the onset of ischemia [5, 26, 47].
Mechanisms Underlying Reperfusion Injury
Prompt restoration of blood flow within the first few hours after ischemic onset is vital
for tissue survival. However, reperfusion of tissues creates a paradoxical effect in that
conditions present in cells undergoing ischemia prime the cells for additional damage activated
by the return of blood supply, damage known as reperfusion injury.
Free Radicals
During ischemia, available ATP is catabolized, resulting in high levels of hypoxanthine, a
required substrate for the xanthine oxidase (XO) reaction. XO exists in high concentrations in
the vascular endothelium, and is simultaneously produced from xanthine dehydrogenase
during ischemia [36, 47]. When blood flow is promptly restored to tissues, a rush of oxygen

10
takes place, which is also needed for XO. As a result, the accumulated hypoxanthine and oxygen
undergo the XO reaction, producing a large amount of reactive oxygen species (ROS) [1, 47].
The massive influx of oxygen also drives the NADPH oxidase reaction, which produces
additional large amounts of ROS due to activated NADPH oxidase in neutrophils that began to
accumulate during ischemia [1, 57, 96]. The considerable amounts of ROS released during
reperfusion activate a deleterious domino effect, as redox signaling facilitates ROS produced
from one enzymatic source to trigger free radical production by other secondary sources, for
example, peroxynitrite formation from nitric oxide (NO) and superoxide [36, 73]. Low levels of
antioxidant enzymes and high levels of polyunsaturated fatty acids make the brain especially
susceptible to oxidative damage during reperfusion [47].
Calcium Overload
H+ ions that accumulated in the extracellular space during ischemia are “washed out”
upon rapid restoration of blood flow. As a result, the activity of the NHE is enhanced, allowing
the large levels of H+ ions accumulated in the cytosol during ischemia to flow down their
concentration gradient, with further increase of intracellular Na + concentration as a result. The
accelerated increase in Na+ ion concentration also drives the Na+/Ca2+ exchanger, increasing
intracellular Ca2+ at an accelerated rate. Upon reperfusion, oxidative phosphorylation resumes,
restoring the electrochemical gradient across the inner mitochondrial membrane (IMM) and
activating the mitochondrial Ca2+ uniporter. Thus, Ca2+ begins to enter the mitochondrial matrix
at a substantial rate, leading to mitochondrial Ca2+ overload [47, 55].
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Opening of Mitochondrial Permeability Transition Pore
Reductions in ATP, oxidative stress, and accumulation of Ca2+ in the mitochondrial
matrix trigger the activation of mitochondrial permeability transition pores (MPTP) in the IMM,
allowing the permeability of molecules less than 1500 Da through the IMM. As a result, Ca 2+
floods into the mitochondrial matrix, triggering swelling and re-collapse of oxidative
phosphorylation and mitochondrial membrane potential. Additionally, swelling causes the
outer mitochondrial matrix (OMM) to rupture, releasing cytochrome c and other toxins into the
cytosol inducing apoptosis and necrosis [11, 42, 72]. Opening of the MPTP is a hallmark of
reperfusion injury, as it is opened within minutes of reperfusion, but closed during ischemia.
Acidic conditions present during ischemia were found to inhibit formation MPTPs, as the low
pH blocks Ca2+ binding to the adenine nucleotide translocase component of MPTPs and
displaces cyclophilin [20].
Proinflammatory Cascades
During the acute phase of ischemia, dying cells release damage-associated molecular
patterns (DAMPs) which activate inflammasomes. However, the activation of inflammasomes,
in particular NLRP3, becomes much more accelerated during reperfusion due to large fluxes of
ROS and intracellular Ca2+, which also activate NLRP3. Activated NLRP3 induces the activity of
pro-inflammatory cytokines, including IL-1β and TNFα, which turn on NF-κB responsive
elements, further triggering the release of pro-inflammatory cytokines. Endothelial cells and
microglia sense cytokines, which produce additional ROS and recruit neutrophils to the
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ischemic site. Thus, a sweeping cascade of inflammation is prompted within minutes of
reperfusion [47, 31, 60, 68, 99]. Multiple studies on reperfusion injury have shown that
increases in the concentration of TNFα is correlated with increased infarct volume, which is
reduced by the delivery of anti-inflammatories [97, 101].
Breakdown of the Neurovascular Unit
In the brain, endothelial cells are surrounded by an extensive blood brain barrier (BBB),
including pericytes, basement membrane, astrocytic end-feet, other glial cells, and neurons,
together making up the neurovascular unit (NVU). Capillaries are enclosed by endothelial cells,
which are connected by tight junction proteins including claudin, occlusion, junctional adhesion
molecule, and zonula occludens-1. Along with adherens junctions, these connections strongly
control the permeability of endothelial cells to prevent free diffusion of molecules. Endothelial
cells are surrounded by pericytes and basement membrane. The main function of pericytes are
to control vessel diameter and clear toxic proteins, while basement membrane serves as the
extracellular matrix component responsible for structural support, cell anchoring, and signal
transduction. Astrocytic end-feet serve to provide communication between endothelial cells
and neurons through neurovascular coupling. The NVU is vital for regulating what enters the
tissue from cerebral capillaries, along with controlling cerebral blood flow for necessary
nutrient delivery [98, 102].
The surge of proinflammatory cytokines and free radicals initiate multiple cascades that
lead to the considerable activation of matrix metalloproteinases (MMP), particularly MMP-3
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and MMP-9. MMP-9 has been shown to play a major role in the degradation of the basement
membrane, occludins, and claudins, leading to a significant disruption of the BBB, and thus
leukocyte infiltration, hemorrhage, and neuronal death. MMP expression is generally low, but
multiple studies have provided evidence of their critical role in damage associated with
ischemia and reperfusion [8, 54, 66, 100]. As a result of BBB breakdown, additional neutrophils
invade the ischemic tissue. Invading neutrophils have been associated with additional
production of free radicals, as well as the release of lytic substances, which aid in the
degradation of the basement membrane and BBB [77].
Capillary No-Reflow Phenomenon
Increased permeability of the BBB due to degradation and collapse of cerebral blood
vessels results in significant swelling of the interstitial space. Furthermore, BBB breakdown in
conjunction with disruption of ionic homeostasis leads to considerable swelling of endothelial
cells and astrocytes of the BBB. Moreover, the surge of free radicals produced by invading
neutrophils triggers prolonged contraction of pericytes surrounding capillaries. The
combination of these factors lead to reduction of luminal diameter, and therefore a capillary
no-reflow phenomenon, as the significant swelling and contraction block blood flow within the
cerebral microvessels (Figure 1). As a result, metabolic wastes cannot be washed out, leading to
further ischemic damage, and thus additional impaction of leukocytes, inflammation, and
disruption of the BBB. This no-reflow phenomenon significantly worsens during reperfusion
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intensifying tissue injury [47, 48]. See Figure 2 for an overview of the ischemic and reperfusion
injury cascades.

Figure 1. Capillary No-Reflow Phenomenon. (a) During normal perfusion, blood flows through
cerebral capillaries that deliver nutrients to the NVU. (b) When blood flow is obstructed during
ischemia, perfusion through capillaries ceases. (c) During reperfusion injury, inflammation and
contraction of pericytes decreases the capillary luminal diameter, restricting the return of blood
flow to cerebral capillaries and inducing additional ischemic damage (modified from Grief &
Eichmann, 2014) [37].
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Figure 2. Ischemic and Reperfusion Injury. Reductions of molecular oxygen and glucose during
ischemia lead to a rapid decrease in ATP levels. This stops the activity of ATPases, accumulating
Na+ and Ca2+ in the cytosol. Decrease in ATP also induces lactic acidosis, stimulating the activity
of the NHE, further increasing cytosolic Na+ and Ca2+. Depolarization of the membrane results,
leading to excessive release of glutamate and further influx of Ca2+. During reperfusion injury,
NHE activity accelerates, raising intracellular Na+ and Ca2+ to cytotoxic levels. ROS are produced
upon reperfusion in combination with ATP loss during ischemia. Decreasing ATP, ROS, and
calcium overload facilitate MPTP opening. ROS and Ca2+ also activate the release of
proinflammatory cytokines, activating MMPs. MMPs cause breakdown of the BBB, causing
swelling and capillary no-reflow. Capillary no-reflow stimulates the release of additional
proinflammatory cytokines. BBB breakdown also increases proinflammatory cytokines and
triggers additional ROS production.
Cell Death During Ischemia and Reperfusion
Necrosis
Ischemic stroke leads to early cell death via necrosis, which is primarily induced by
disruption of ion homeostasis leading to cell and organelle swelling. During ischemia and
reperfusion, massive influxes of Na+ and Ca2+ into the cytoplasm, mitochondria, and
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endoplasmic reticulum promote large influxes of water, especially through aquaporins present
in astrocytic end-feet, and thus cytotoxic edema [2, 12]. Furthermore, excessive activation of
glutamate receptors, significant reductions in intracellular pH, and profound depletions of ATP
are also associated with irreversible necrotic cell death, all of which occur during ischemic and
reperfusion injury. Ultimately, mitochondrial and plasma membrane rupture release activated
proteases and mitochondrial toxins, spreading the necrotic damage to neighboring cells [12].
Additionally, recent evidence suggests that multiple pathways of regulated necrosis of cells are
also driven by ischemia and reperfusion, including necroptosis, MPTP-dependent regulated
necrosis, parthanatos, ferroptosis, and oxytosis [6, 16, 21, 47, 89].
Apoptosis
Although necrosis is the primary method of cell death detected during ischemia and
reperfusion, apoptotic cell death has also been observed, particularly during reperfusion.
Apoptosis is generally characterized by cell shrinkage, nuclear fragmentation, and chromatin
condensation. Apoptosis is comprised of two pathways, the extrinsic pathway associated with
the binding of ligands, for example TNFα, to proinflammatory receptors, and the mitochondrial
pathway, characterized by release of cytochrome c and Ca2+ activated caspases, induced by Bax
and Bak proteins [14, 47, 52]. Ischemic and reperfusion injury mechanisms have been found to
induce apoptosis, markedly the large production of free radicals, NMDA receptor activation,
calcium influx, lipid peroxidation, and apoptogenic factors released from MPTPs [12]. Evidence
suggests, however, that apoptotic cell death primarily occurs during reperfusion injury, as pro-
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apoptotic Bcl2 proteins upregulated during ischemia are redox sensitive, and therefore only
sufficiently activated by the oxidative stress encountered during reperfusion injury [47]. CNS
cells most susceptible to apoptosis primarily include neurons neighboring the necrotic region
[12].
Pre- and Post-Conditioning
Extensive evidence exists targeting and supporting the mechanisms of reperfusion
injury. Some of the first studies to confirm that reperfusion injury exists were those involving
ischemic pre- and post-conditioning in myocardial infarction (MI). Ischemic pre-conditioning
was first proposed by Murry, Jennings, and Reimer (1986), who concluded that exposing canine
hearts to brief periods of ischemia and reperfusion prior to MI protected a significant number
of myocytes in the myocardium following MI, highlighted by the activation of multiple
cardioprotective signaling pathways [67]. Similarly, post-conditioning was discovered by Zhao
and colleagues in 2003, who found that subjecting canine hearts to multiple brief periods of
ischemia and reperfusion following MI resulted in a 44% reduction of infarct size [103].
Although the exact mechanisms of post-conditioning are unclear, it has been proposed that the
brief periods of aerobic metabolism restoration activate multiple protective pathways leading
to the reduction of edema, oxidative stress, and neutrophil accumulation post-MI by inhibiting
the opening of MPTPs. This inhibition of MPTPs by post-conditioning first provided direct
evidence of reperfusion injury, since MI was significantly reduced by this inhibition.
Furthermore, the mechanisms of reperfusion injury in MI can sufficiently be applied to ischemic
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events in other tissues. Importantly, post-conditioning has since been shown to have
therapeutic effects following MI in humans, confirming that reperfusion injury after ischemia
exists in humans and is a clinical target [15, 39, 43].
Long-term Damage
Inflammation
Inflammatory damage induced by ischemic stroke can progress for days to weeks
following the initial ischemic insult. Extensive literature provides evidence that leukocyte
adhesion molecules, infiltrating macrophages and neutrophils, and activated microglia can
persist in the ischemic and perilesional long-term following reperfusion [7, 45]. The remaining
inflammatory cells continue to release free radicals, while also contributing to the capillary noreflow phenomenon, furthering damage and cell death. Furthermore, residing inflammatory
cells continue to release pro-inflammatory markers, which were found to be elevated in human
serum samples 24 hours post-stroke [65]. Long-term inflammation post-stroke is often assessed
by analyzing activation of microglia and infiltrating leukocytes, because both cell types have
been shown to persist for weeks after ischemia and reperfusion. Common markers employed
include ionized calcium binding adaptor molecule 1 (Iba1) and cluster of differentiation 68
(CD68). Iba1 is a calcium-binding protein specific to microglia, and thus Iba1 antibodies are used
to stain for both resident and activated microglia. CD68 is a glycoprotein heavily expressed in
macrophages and other mononuclear phagocytes. CD68 antibodies (most commonly ED1) are
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often used to detect infiltrating macrophages in the parenchyma as well as phagocytic microglia
[19, 71].
Ischemic Core and Penumbra
Two types of tissue injury are observed in the hours following ischemic stroke, termed
the core and the penumbra. The ischemic core is defined as tissue receiving less than 20%
baseline blood flow during the ischemia, and results in glial and neuronal death within minutes
to hours. On the other hand, the penumbra also undergoes significant reduction in blood flow,
but the tissue is partially perfused by collateral blood flow at levels greater than 20% of
baseline. Reductions in ATP continue to initiate damage, however, energy failure occurs at a
smaller degree than that seen in the core. Neurons in the penumbra can remain salvageable for
hours if blood flow is promptly restored or if these cells are more resistant to injury [7, 65]. The
penumbra generally surrounds the ischemic core, and was described by Astrup et al. (1981) as
appearing similar to the “half-shaded zone around the center of a complete solar eclipse” [9].
However, worsening inflammation consistent with a lack of prompt restoration of blood flow
will eventually drive the damaged cells in the penumbra to irreversible injury, increasing the
size of the ischemic core.
Treatment for Ischemic Stroke
Recombinant Tissue Plasminogen Activator and Mechanical Thrombectomy
Treatment for ischemic stroke is severely lacking. Currently, there is only one
pharmacological treatment approved by the U.S. Food and Drug Administration for ischemic
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stroke, and it was approved in 1996 [95]. Recombinant tissue plasminogen activator (rtPA)
(Alteplase) cleaves plasminogen at its Arg561-Val562 bond to form plasmin, an active serine
protease. Plasmin acts as a thrombolytic by cleaving cross-links between fibrin molecules to
initiate the breakdown of clots. Although rtPA has been shown to improve outcomes, it can
only be administered within the early hours after symptom onset due to increased risk in
complications (e.g. hemorrhage) after this time window. It has numerous contraindications
including location and size of the thrombus and presence of uncontrolled hypertension, which
only allows approximately 6-8% of patients to receive treatment [18, 23, 44]. When patients
present with ischemic stroke outside the time window, or with rtPA contraindications,
mechanical thrombectomy is often performed. Thrombectomy involves the insertion of a
catheter into the affected artery, in which a stent is inserted to remove the thrombus. There
are greater advantages to the use of mechanical thrombectomy including the ability to remove
larger clots and a longer time window for treatment, and multiple recent clinical trials have
shown it to be more beneficial than in patients treated with rtPA, with 46% of patients showing
substantial beneficial outcome [34, 35]. However, thrombectomy must be performed by
trained specialists at sophisticated medical centers. In the United States, only approximately
60% of the population has access to hospitals with stroke teams [56].
Currently, mechanical thrombectomy in combination with rtPA is the standard of
treatment for ischemic stroke in eligible patients [76]. However, a recent clinical trial presented
at the American Heart Association/American Stroke Association International Stroke
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Conference in February 2020 suggests that mechanical thrombectomy alone is not inferior to
that of mechanical thrombectomy combined with rtPA, and there was significantly less cerebral
hemorrhage observed in the mechanical thrombectomy only group than that combined with
rtPA [94].
Targeting Reperfusion Injury
Despite the apparent success of mechanical thrombectomy, it is still insufficient, given
that appx. 50% of patients do not see significant recovery, and 15% of those patients do not
survive [46]. Thus, there is an urgent unmet need for a drug that successfully and substantially
reduces brain damage secondary to ischemic stroke. There has been a recent push to target
reperfusion injury, as reperfusion injury significantly adds to the damage initiated during
ischemia, as confirmed first by pre- and post-conditioning studies, and now by extensive
literature. Furthermore, reperfusion injury is thought to catalyze the transition from reversible
to irreversible cell death, due to the important role played by inflammation, and targeting
reperfusion injury with pharmacological agents could potentially salvage the penumbra [64,
65]. Most importantly, despite moderate success observed with rtPA and mechanical
thrombectomy, both treatments are designed to rapidly restore blood flow, which enhances
the reperfusion paradox. Despite increasing research for pharmaceutical treatments targeting
reperfusion injury, no studies to-date have made it past clinical trials.
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Bradykinin
Many studies suggest that while the hormone bradykinin is generally a proinflammatory
neuropeptide, it plays a protective role in brain damage, particularly ischemia and reperfusion
[4, 24, 46, 78, 81, 82). It has been supported that when bound to its B2 receptor, bradykinin
induces the formation of small amounts of NO and prostacyclin (PGI2). At low levels, NO and
PGI2 act as antiadhesive agents, inhibiting leukocyte adhesion and promoting BBB function. The
bradykinin B2 receptor is a G-protein coupled receptor on vascular endothelial cells that has
been found to be upregulated after cerebral ischemia [78]. The B2 receptor is known to form
heteromers with endothelial nitric oxide synthase, which catalyzes the formation of NO from Larginine and molecular oxygen when induced [32, 61]. When released by the B2 receptor, NO
and PGI2 diffuse through plasma membranes and inhibit NF-κB, which generally attenuates
expression of proinflammatory chemokines and leukocyte adhesion molecules. Inhibition of NFκB, activating the extracellular signal regulated kinase 1/2 pathway, is a key player in the
inflammation cascade induced by reperfusion injury. While overstimulation of both the
bradykinin B1 and B2 receptors has been shown to attenuate inflammation after stroke, there
is evidence that activation of the B2 receptor specifically promotes the survival of glial cells,
reduces BBB degradation, and inhibits apoptosis and necrosis via blocking the opening of
MPTPs and releasing Ca2+ from intracellular stores by activating protein kinase C, all of which
are mechanisms associated with reperfusion injury [24, 47, 78, 79, 81] Therefore, activation of
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the bradykinin B2 receptor is a significant potential approach to reducing reperfusion injury
after ischemic stroke.
Endogenous bradykinin concentrations are increased during hypoxia, however not to
levels high enough to inhibit tissue damage. Furthermore, bradykinin administered directly is
highly associated with angioedema through its vasodilating properties [22]. Aminopeptidase P2
(APP2), an inactivator of bradykinin on the luminal plasma membrane of the vascular
endothelium (outside BBB), has been extensively studied by Dr. Simmons’s lab. APP2 is located
on vascular endothelium cells, and shown to inactivate bradykinin by cleavage and removal of
the N-terminal arginine [58, 85] (Figure 3). APP2 requires a proline residue in the second
position of a substrate, and therefore is very specific for inactivating bradykinin. Thus, a potent
inhibitor of APP2, ST-115, was designed and patented by Dr. Simmons’s lab (Figure 3, 4).

Figure 3. ST-115 Inhibits Aminopeptidase P2. Aminopeptidase functions under normal
conditions to inactivate bradykinin by cleaning its Arginine in the first position. Apstatin and ST115 inhibit this action, thus blocking bradykinin inactivation and increasing its endogenous
concentration.
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Figure 4. ST-115 Mechanism of Action. Under ischemic conditions, bradykinin is upregulated
and binds to its B2 receptor. However most bradykinin is inactivated by APP2, and it does not
reach levels high enough to exhibit a protective effect. ST-115 acts to inhibit APP2, thus
allowing bradykinin to reach levels high enough that when bound to its B2 receptor, activate
the release of NO and PGI2 which block reperfusion injury.
ST-115, An Aminopeptidase P2 Inhibitor
The APP2 inhibitor apstatin was initially designed by the Simmons lab and used for
preliminary studies, however the more potent inhibitor ST-115 has since been designed. ST-115
is a thiol-containing peptidomimetic that contains tertiary amide bonds to make it highly
resistant to protease cleavage (Figure 5). It is water soluble (>50mg/mL) and therefore designed
for intravenous injection. ST-115 is highly specific for the active site of APP2 (IC 50 = 3.7nM), and
assays thus far have not shown any other peptidase to be inhibited by ST-115 in the low
nanomolar range (Figure 6, Table 1). ST-115 has the ability to enter the capillaries of the
ischemic brain during reperfusion, and by specifically inhibiting APP2, has the capability of
increasing endogenous bradykinin levels low enough to avoid increased permeability of the
BBB, but high enough to produce protective levels of NO and PGI 2 in the brain (Figure 4).
Apstatin has previously been shown in the Jones lab to exhibit cardioprotection, and ST-115 has
been shown in the Simmons lab to reduce acute kidney injury (Figure 7). Furthermore,
preliminary studies of ST-115 delivered following 45 minutes of ischemic stroke suggest that ST115 promotes functional recovery (Figure 7). Therefore, ST-115 has the capability to
significantly reduce reperfusion injury in various tissues.
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Figure 5. Structure of ST-115. ST-115 is a thiol-containing peptidomimetic that contains tertiary
amide bonds to make it highly resistant to protease cleavage.

Figure 6. ST-115 Inhibition Curve. The IC50 of ST-115 is 3.7nM, which is the concentration of ST115 that inhibits APP2 by 50%. Each point is the mean of four values. The APP2 enzyme used for
this data was highly purified from human kidney.
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Table 1. ST-115 Specificity. ST-115 is highly specific for the active site of APP2, and assays
performed in the Simmons lab have not shown ST-115 to inhibit any other peptidases in the
low nanomolar range. All enzymes are human, and most are recombinant. IC 50+ values are the
concentration of ST-115 that inhibited the peptidase by 50%.
Enzyme

IC50 (nanomolar)

Aminopeptidase P2

3.7

Aminopeptidase P1

660

Aminopeptidase M

>11,000

Angiotensin-converting enzyme

68,000

Neprilysin

14,000

Membrane dipeptidase

>10,000

Prolidase

>60,000

Cytosol alanyl aminopeptidase

>60,000

Dipeptidylpeptidase IV

>90,000

Endothelin-converting enzyme-1

>270,000

Aminopeptidase A

>250,000

Aminopeptidase B

>100,000

Angiotensin-converting enzyme-2

>210,000

Endoplasmic reticulum aminopeptidase 2

>200,000

ADAM-9

>200,000

Thimet oligopeptidase

40,000

Neurolysin

80,000

MMP-1

270,000

MMP-2

>200,000
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Figure 7. Apstatin and ST-115 Preliminary Data. (A) Cardioprotection. Mice underwent left
coronary artery occlusion for 30 minutes followed by 4 hours of reperfusion. Apstatin was
administered 5 minutes before reperfusion. Apstatin treatment significantly decreased infarct
size of the left ventricle. HOE140 = bradykinin B2 receptor antagonist. (B) Renoprotection. Mice
underwent bilateral ischemic for 25 minutes followed by 2 days of reperfusion. Apstatin and ST115 (10µg/kg) were administered 5 minutes before reperfusion. Blood urea nitrogen (BUN), a
marker of acute kidney injury, was significantly lower in mice treated with apstatin and ST-115.
(C) Functional recovery. Rats underwent 45 minutes of tMCAO and bilateral CCA occlusion
followed by reperfusion. ST-115 (16µg/kg) was administered 5 minutes before reperfusion. Rats
were assessed using the skilled forelimb reaching task behavior was represented as a success
score (number of successful grasps out of 20 attempts). Rats treated with ST-115 exhibited
significantly higher success scores on post-operative days 8-11 and day 12 compared to controls
(taken from Sethupathi et al.) [80].
Clinical Relevance
The current treatment approach to ischemic stroke, rtPA and/or mechanical
thrombectomy, while moderately successful, also strongly enhances reperfusion injury. ST-115
is designed to be administered intravenously to a patient undergoing ischemic stroke just prior
to these reperfusion procedures. Once reperfusion is initiated, ST-115 will enter the ischemic
tissue, inactivate APP2 and increase endogenous bradykinin. ST-115 thus can strongly enhance
the efficacy of rtPA and mechanical thrombectomy procedures and limit tissue injury.
Transient Middle Cerebral Artery Occlusion
Transient Middle Cerebral Artery Occlusion (tMCAO) is currently the gold standard in
ischemia and reperfusion injury research with rodents, as it has been designed for clinical
relevance. tMCAO is performed either extraluminally, with the use of clamps or needles, or
intraluminally by the insertion of a microfilament to occlude the vessel. Mechanical
thrombectomy in humans allows for rapid removal of occlusion and simultaneous reperfusion
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of the vessel, and both tMCAO models mimic this mechanism. This is particularly important for
reperfusion injury studies, as the rapid restoration of blood flow is vital for induction of
reperfusion injury. Although the model is not without limitations, including vessel damage and
discrepancies between rodent and human infarct sizes, it is currently the best model in the
literature to study pharmacology targeting reperfusion injury [17, 93].
Horizontal Ladder Rung Walk
A common and important behavioral assessment of damage to the primary motor
cortex in rodent studies of MCA ischemic stroke is the horizontal ladder rung walk, which
assesses skilled walking across a horizontal ladder. This test has been proven sensitive to motor
cortex injury in both the literature and multiple studies in the Kartje lab [62, 92]. It is
additionally a preferred method for MCA damage assessment because walking across a
horizontal surface involves both cortical and subcortical motor systems, both of which can be
affected by ischemic stroke models in rodents [62].

CHAPTER THREE
MATERIALS AND METHODS
Experimental Design
Two experiments were conducted for this study (Figure 8). The first experiment was
designed to assess functional recovery and reduced neurological injury 24-hours postreperfusion in rats treated with ST-115. Rats underwent tMCAO surgery (n=28) in five separate
cohorts, and behavioral testing (n=20) in three separate cohorts (Table 2). Rats were excluded
from the study if there were significant problems with MCA occlusion (e.g. rupture, too deep
for occlusion) or if they died in surgery. Three rats were excluded from the study for these
reasons (Table 2). Behavioral testing included assessment via the horizontal ladder rung walk.
Animals were sacrificed 24-hours post-reperfusion, and brains were removed and stained with
2,3,5-triphenyltetrazolium chloride (TTC) to measure stroke lesion volume and brain edema.
The second experiment aimed to assess long-term functional recovery and reduced
neurological injury. Rats (n=8) underwent tMCAO surgery and behavioral testing as one cohort
(Table 2). Behavioral testing was assessed via horizontal ladder rung walk. Animals were
sacrificed and perfused 6-weeks post-reperfusion. Brains were removed, fixed, and sectioned
for histological studies. Brain sections were stained with toluidine-blue to measure stroke lesion
volume, and triple-stained with Iba1/ED1/DAPI to assess microglia patterns.
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Figure 8. Experimental Timeline. All rats underwent baseline behavioral assessment prior to
tMCAO. 5 minutes prior to reperfusion, rats received either vehicle or ST-115 injection. After 90
minutes of tMCAO, MCAs were reperfused. 24 hours post-reperfusion, rats were assessed for
deficits. (A) Rats were euthanized after assessment 24 hours post-reperfusion, and brains were
extracted and stained with TTC for lesion analysis. (B) Rats were additionally assessed for deficits
at 2 weeks and 6 weeks post-reperfusion. After assessment at 6 weeks, rats were perfused, and
brains were stored for further lesion and immunohistochemical analyses.
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Table 2. Rat IDs by Cohort. Survival times are noted for each cohort in parentheses. tMCAO for
cohorts 1 and 2 were performed before joining the project, but sections were analyzed for the
lesion analysis and brain edema. IDs with an asterisk were not available for lesion analysis or
edema. IDs with a plus sign were used for lesion analysis, but not edema. IDs shaded in gray were
excluded from the study.
Cohort
1 (24 hr.)
2 (24 hr.)
3 (24 hr.)
4 (24 hr.)
5 (6 wks.)
KJ-9+
WS-C2-03
ML-1
ML-11
ML-21
KJ-13
WS-C2-04
ML-2
ML-12
ML-22
KJ-14
WS-C2-05+ ML-3
ML-13+
ML-23
WS-C2-09+ ML-4
ML-14
ML-24
WS-C2-10
ML-5
ML-15*
ML-25
ML-6
ML-16
ML-26
ML-7
ML-17
ML-27
ML-8
ML-18
ML-28
ML-9
ML-19*
ML-10
ML-20
Animal Subjects
36 10-week-old male Sprague-Dawley rats (Harlan, IN) were used for this study. Rats
were housed two per cage in non-sterile micro-isolator caging with a filter top in a fully
accredited animal care facility. Rats were kept on a 12-hour light/dark cycle and food and water
was available ad libitum. Experimental groups were as follows: tMCAO + vehicle/24-hour
survival (n=13), tMCAO + ST-115/24-hour survival (n=15), tMCAO + vehicle/6-week survival
(n=4), and tMCAO + ST-115/6-week survival (n=4) (Table 3). All surgeries and behavioral tests
were conducted between 10am-5pm, Monday through Friday. Animal experiments were
approved by the Institutional Animal Care and Use Committee (IACUC) at Edward Hines Jr.
Veterans Affairs Hospital, permit #H18-006.
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Table 3: N for Experimental Groups
N
tMCAO + vehicle/24-hour survival

13

tMCAO + ST-115/24-hour survival

4

tMCAO + vehicle/6-week survival

15

tMCAO + ST-115/6-week survival

4

ST-115 Preparation
Solid ST-115 was custom synthesized by CPC Scien-tific (Sunnyvale, CA; a cGMP-capable
company) as previously described [84]. ST-115 is stable in solid form for at least five years. Just
prior to injection, 1mL sterile saline was added to one vial of solid ST-115 prepared by Dr.
Simmons (one rat per vial), and vortexed until thoroughly dissolved. 16µg/kg dose of ST-115
was previously determined to exhibit the most protective effect, and thus this dose was chosen
for this study (Figure 9).
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Figure 9. ST-115 Dose-Response. Doses were given with 45-minute tMCAO and infarct volume
analyzed 2 days post-reperfusion. Horizontal lines represent the means.
Transient Middle Cerebral Artery Occlusion
All animals underwent 90 minutes of transient extraluminal middle cerebral artery
occlusion (tMCAO) with bilateral common carotid artery occlusion. Animals were initially placed
in a plexiglass box and anesthetized via inhalation with 5% 75mg/mL isoflurane in oxygen. For
the remainder of the surgery, rats were kept anesthetized with 2-3% isoflurane in oxygen via
nose mask. Core body temperature was maintained between 37 and 38°C during the procedure
with a heating pad. At the beginning of the procedure, a midline longitudinal cervical neck
incision was made, and the bilateral common carotid arteries (CCA) were isolated. Rats were
then placed in a stereotaxic frame and a 2cm vertical incision was made between the left eye
and ear. The temporalis muscle was then retracted, and a burr hole was made over the left
parietal cortex to expose the left MCA. The MCA was followed to where it transverses the rhinal
sulcus and was lifted with a MV-135 needle such that blood flow was visibly occluded (Figure
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10). Immediately following the onset of occlusion, both CCA were transiently occluded with
microaneurysm clips. After 85-minutes of occlusion, rats were intravenously injected with
0.6mL vehicle (sterile saline) for controls, or 0.6-0.7mL ST-115 in saline (16µg/kg) through the
tail vein. Five minutes following intravenous injection of saline or ST-115, the MV-135 needle
and CCA clips were removed to allow for reperfusion. Once incisions were closed, rats were
kept warm and monitored during the post-op period in separate cages until fully awake, and
then placed back in their home cage. All surgical procedures were performed by Shih-Yen Tsai.

Figure 10. Transient Middle Cerebral Artery Occlusion. The MCA is shown before (A) and during
(B) tMCAO, and during reperfusion (C). Black lines outline the MCA. Black arrows point to blood
flow in the MCA. White arrow points to absence of blood flow.
An extraluminal model was justified for experiments for multiple reasons. First, the
extraluminal model is preferred to the intraluminal filament model due to the decreased risk
for vessel damage with respect to the intraluminal model. Furthermore, intraluminal models
are increasingly becoming clinically irrelevant because of the complete blockage of the artery
with the filament, while vessel occlusion in human strokes is rarely complete. This leads to
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much larger infarct volumes, which are not typically seen in human strokes [190]. The transient
extraluminal model has been used extensively in the Kartje lab.
90 minutes of tMCAO was also justified for this study. The most common durations seen
in the literature for rat tMCAO studies are between 60-120 minutes. Occlusion past 120
minutes often results in spontaneous hypothermia, which is rare in humans and therefore
reduces the clinical efficacy [90]. Previous ST-115 data using a 45-minute tMCAO model
frequently produced very small stroke size, consistent with stroke sizes seen in Sprague-Dawley
rats in the literature [33]. Furthermore, the 60-120 minute range is more applicable for studies
regarding reperfusion, as this time period results in delayed neuronal death in the ipsilateral
hemisphere consistent with reperfusion injury [90]. Therefore, a 90-minute tMCAO model was
chosen for this study.
Blood Glucose
Blood glucose was measured with the Bayer Contour Next EZ Blood Glucose Monitoring
System and Bayer Contour Next Blood Glucose Test Strips (Bayer, Leverkusen, Germany). Blood
resulting from the tail vein injection during vehicle/drug delivery was measured for glucose
level and recorded. Blood glucose measurement was repeated five minutes after vehicle/drug
delivery, also with blood from the tail vein.
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Horizontal Ladder Rung Walk
The ladder rung walking test is used to assess forelimb and hindlimb placing, stepping,
and inter-limb coordination in rats with a cortical lesion. The dimensions of our ladder mirrored
those originally developed by Metz and Whishaw [62]; horizontal ladder was 1m in length and
10cm in width, with randomly spaced, thin metal rungs measuring 1cm to 5cm apart and
surrounded with a clear plexiglass wall on either side. The ladder was placed 30cm above the
ground, with the rat’s home cage at the end of the ladder. For each trial, animals were guided
to walk from one end to the other in one direction, and each animal was guided in the same
direction to keep consistency between animals and rung pattern. All trials were videotaped for
later analyses. Videos were assessed for the number of total steps and number of slips taken by
the right forelimb during each trial. A slip was defined when the limb either slipped off the
rung, or missed the rung, both resulting in a disruption of weight placement (Figure 11). All rats
underwent three trials prior to tMCAO for baseline measurement. Animals in the 24-hour
survival cohort were measured in three additional trials measured at 24 hours post-reperfusion.
Animals in the 6-week survival cohort underwent three additional trials at 24 hours, 2 weeks,
and 6 weeks post-reperfusion. The number of total steps and slips were recorded for each trial,
and data were analyzed as the number of slips per 10 steps taken.
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Figure 11. Horizontal Ladder Rung Walk Slip. (A) Normal step of the right forepaw. (B) Slip of
the right forepaw. Black arrows point to the right forepaw.
Euthanasia, Transcardial Perfusion, and Tissue Processing
All animals were first anesthetized with 5% isoflurane in oxygen through inhalation.
Once anesthetized, animals received Euthasol Solution overdose (390mg/kg) via intraperitoneal
injection. Decapitation and/or perfusion proceeded once animals ceased respiration and were
unresponsive. Animals in the 24-hour survival cohorts were quickly decapitated and brains
were rapidly removed. Brains from these cohorts were then stained with 2,3,5triphenyltetrazolium chloride (TTC; Sigma Aldrich, St. Louis, MO). Transcardial perfusions via
bilateral thoracotomy were performed on animals in the 6-week survival cohort following
euthanasia. Rats were first perfused with 200-250mL heparinized saline (25mL/min) followed
by 300-350mL 4% paraformaldehyde (PFA; Sigma Aldrich) in phosphate buffered saline (PBS).
Rats were then decapitated and brains were removed as normal. Brains from this cohort were
fixed in 4% PFA overnight, followed by cryoprotection in 30% sucrose (Sigma Aldrich) in 0.1M
phosphate buffer pH 7.4. After appx. three days in sucrose solution, brains were frozen in
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optimal cutting temperature compound (Sakura FineTek USA, Torrance, CA) and stored at 80°C. Brains were cut on a Leica CM1850 cryostat in serial 4µm coronal sections and stored for
further studies in either 0.01% sodium azide (Thermo Fisher Scientific, Waltham, MA) in PBS or
antifreeze buffer.
2,3,5-Triphenyltetrazolium Chloride Staining
All brains in the 24-hour survival cohort were stained with TTC to assess infarct volume.
TTC stains metabolically active tissues red, and metabolically inactive tissues white. Following
decapitation, brains were rapidly removed and sectioned at 2mm thickness from cerebellum to
cerebrum. Sections were stained in 2% TTC in saline in the dark for approximately. 20 minutes
at room temperature. Sections were then transferred to 4% PFA and stored at 4°C.
Sections from some brains did not stay together, and were not available do be analyzed
for lesion or edema. This occurred for two animals in the study (Table 2). Additionally, sections
were not used for analyzing edema if the ipsilateral hemisphere volume was measured to be
less than that of the contralateral hemisphere, potentially indicating uneven sectioning. Four
rats were excluded from the study for these reasons (Table 2).
Nissl Staining
Nissl stain is commonly used in the Kartje lab to measure infarct size in long-term stroke
studies. Toluidine-blue is used to stain for Nissl substance, which are granules composed for
rough endoplasmic reticulum [12]. Every 1 in 13 free-floating sections were serially mounted on
gelatin-coated slides and dried at 37°C for two days. Once cooled to room temperature,
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sections were stained for Nissl with toluidine-blue for infarct volume analysis. Slides were
washed in deionized water for 5 minutes, followed by increasing (50%, 70%, 95%, 100%) and
decreasing (95%, 70%, 50%) ethanol concentrations for 1 minute each. Slides were then rinsed
in deionized water and placed in 2.5% toluidine-blue (Ricca Chemical Company, Arlington, TX) in
Walpole buffer for 10 minutes. Slides were quickly rinsed with increasing concentrations of
ethanol (50%, 70%, 95%), followed by rinses in 95% ethanol + 10% acetic acid, 95% ethanol, and
100% ethanol x2. Slides were placed in two changes of Citrisolv (Thermo Fisher Scientific) for
five minutes each. Coverslips were mounted with Permount (Thermo Fisher Scientific) and
dried for two days at room temperature.
Infarct Volume and Brain Edema
TTC-stained sections (excluding olfactory bulb and cerebellum) were placed on slides
ventral-side down and scanned to a desktop computer using a Canon CanoScan LiDE 700F
scanner. Nissl-stained sections on slides were scanned in a similar manner. Contralateral, intact
ipsilateral, and infarct areas were measured using Adobe CS5 (47 pixels/mm). For TTC-stained
sections, 5-7 sections were analyzed, depending on the size of the brain. For Nissl-stained
sections, sections starting with the genu of corpus callosum (appx. 1.60mm anterior to bregma)
and ending with field CA3 of the hippocampus (appx. 4.16mm posterior to bregma) were
analyzed [74]. Corrected infarct areas (corrected for edema) and infarct volume was calculated
as follows [53]:
𝐶𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑 𝑖𝑛𝑓𝑎𝑟𝑐𝑡 𝑎𝑟𝑒𝑎 =

𝑖𝑛𝑓𝑎𝑟𝑐𝑡 𝑎𝑟𝑒𝑎 𝑥 𝑐𝑜𝑛𝑡𝑟𝑎𝑙𝑎𝑡𝑒𝑟𝑎𝑙 ℎ𝑒𝑚𝑖𝑠𝑝ℎ𝑒𝑟𝑒 𝑎𝑟𝑒𝑎
𝑖𝑛𝑡𝑎𝑐𝑡 𝑖𝑝𝑠𝑖𝑙𝑎𝑡𝑒𝑟𝑎𝑙 ℎ𝑒𝑚𝑖𝑠𝑝ℎ𝑒𝑟𝑒 𝑎𝑟𝑒𝑎
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𝐼𝑛𝑓𝑎𝑟𝑐𝑡 𝑣𝑜𝑙𝑢𝑚𝑒 =

∑ 𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑 𝑖𝑛𝑓𝑎𝑟𝑐𝑡 𝑎𝑟𝑒𝑎
𝑥 100
∑ 𝑐𝑜𝑛𝑡𝑟𝑎𝑙𝑎𝑡𝑒𝑟𝑎𝑙 ℎ𝑒𝑚𝑖𝑠𝑝ℎ𝑒𝑟𝑒 𝑎𝑟𝑒𝑎

TTC-stained sections were also analyzed for brain edema, calculated as follows [153]:
𝐵𝑟𝑎𝑖𝑛 𝑒𝑑𝑒𝑚𝑎
=

∑ 𝑖𝑛𝑡𝑎𝑐𝑡 𝑖𝑝𝑠𝑖𝑙𝑎𝑡𝑒𝑟𝑎𝑙 ℎ𝑒𝑚𝑖𝑠𝑝ℎ𝑒𝑟𝑒 𝑎𝑟𝑒𝑎 − ∑ 𝑐𝑜𝑛𝑡𝑟𝑎𝑙𝑎𝑡𝑒𝑟𝑎𝑙 ℎ𝑒𝑚𝑖𝑠𝑝ℎ𝑒𝑟𝑒 𝑎𝑟𝑒𝑎
𝑥100
∑ 𝑐𝑜𝑛𝑡𝑟𝑎𝑙𝑎𝑡𝑒𝑟𝑎𝑙 ℎ𝑒𝑚𝑖𝑠𝑝ℎ𝑒𝑟𝑒 𝑎𝑟𝑒𝑎
Immunohistochemistry
Brain sections from the 6-week survival cohort (n=8) were analyzed for microglia

patterns via immunohistochemistry. Every 1 in 13 free-floating sections were triple stained with
fluorescent antibodies for Iba1 (Fujifilm Wako 019-19741), CD68 (via ED1) (AbD Serotec
MCA341R), and DNA (via 4’,6-diamidino-2-phenylindole; DAPI). DAPI is a blue-florescent DNA
stain that exhibits fluorescence when bound to AT regions of double-stranded DNA [19, 25, 71].
Two sections with lesion, 520 µm apart (appx. 0.20mm and 0.48mm anterior to Bregma)
[74], per brain were stained. Sections were blocked with CuSO4 for 15 minutes, then washed
with 0.2% Tween20 in 0.01M PBS (PBST) 3x, 10 minutes each. Primary antibodies were added
(Table 4) with 5% normal goat serum and incubated overnight at 4°C. The next day, sections
were washed 3x with PBST, 10 minutes each. Secondary antibodies (Table 4) were incubated
with normal goat serum (Thermo Fisher Scientific) for two hours in the dark at room
temperature. Sections were then washed in the dark once with PBST for 10 minutes, once with
DAPI for 10 minutes, and once with PBST for 10 minutes. Sections were added to gelatin-coated
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slides and coverslipped with Fluoromount G anti-fade mounting media. Slides were stored in
the dark at 4°C.
Table 4: Antibodies and Markers.
Marker/Antigen
Ionized binding
adapter molecule 1
Cluster of
differentiation 68
4',6-diamidino-2phenylindole

Abbreviation
Iba1
CD68 (ED1)
DAPI

Function
Cell type
calcium
microglia,
binding protein macrophages
mononuclear
glycoprotein
phagocytes
microglia,
DNA binder
macrophages

Source;
Concentration
Rabbit; 1:1000
Mouse; 1:500
Immunofluorescence

Triple-stained sections were analyzed with a Leica TCS SPE confocal microscope using
Leica Application Suite X cellular imaging software. For each section, 6, 275µm x 275µm images
were taken in the perilesional area, dorsal to ventral, and corresponding images were taken in
the unaffected contralateral hemisphere as a control (Figure 18). Iba1 and ED1-stained cells
were counted when overlapped with DAPI stained nuclei.
Statistical Analyses
All statistical analyses were performed using GraphPad Prism version 8. Repeated measures
two-way ANOVA was used to compare blood glucose levels between treatment groups at time
of vehicle/drug delivery and 5 minutes post-vehicle/drug delivery. Repeated measures two-way
ANOVA was also used to measure ladder walk slips between treatment groups at baseline, 24
hours, 2 weeks, and 6 weeks post-reperfusion. All other statistical analyses used the Mann
Whitney U test. This nonparametric test was chosen due to the presence of ratios as well as
non-normal distribution of data and small sample sizes in the six-week studies. Significance was
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determined as p < 0.05. Degrees of protection were calculated by dividing the difference
between the medians by the median of the vehicle group. This calculation does not provide
significance, but rather shows a trend in the differences between medians.

CHAPTER FOUR
RESULTS
Neurological Injury
Infarct Volume 24 Hours Post-Reperfusion
Infarct volume was quantified 24 hours post-reperfusion with TTC stain. No statistically
significant difference was found between treatment groups (Mann-Whitney, p>0.05) (Figure
12). Degree of protection by ST-115 was 46%.

Figure 12. Infarct Volume 24 Hours Post-Reperfusion. (A) Representative infarcts for vehicle
(left) and ST-115 (right) treated groups. White areas indicate infarcted tissue. (B) Infarct volume
(%). Bars represent medians with interquartile range. (C) Log-transformed distribution of the
data. Bars represent the mean.
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Brain Edema 24 Hours Post-Reperfusion
Brain edema was quantified 24 hours post-reperfusion with TTC stain. A significant
reduction in edema was found in the ST-115 treated group vs. untreated controls (MannWhitney, p<0.05) (Figure 13). Degree of protection by ST-115 was 58%.

Figure 13. Brain Edema 24 Hours Post-Reperfusion. Brain edema (%). Bars represent medians
with interquartile range. * = p<0.05.
Infarct Volume 6 Weeks Post-Reperfusion
Infarct volume was quantified six weeks post-reperfusion with Nissl stain. No statistically
significant difference was found between treatment groups (Mann-Whitney, p>0.05) (Figure
14). Degree of protection by ST-115 was 49%.
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Figure 14. Infarct Volume 6 Weeks Post-Reperfusion. (A) Representative Nissl-stained sections
with lesion from vehicle (top) and ST-115 (bottom) treated groups. (B) Infarct volume (%). Bars
represent medians with interquartile range.
Blood Glucose
Blood glucose levels were measured in a small cohort at two time points: time of
vehicle/drug delivery, and five minutes post-vehicle/drug delivery. No statistical differences
were found between treatment groups, or between time points for either group (2-way
repeated measures ANOVA, p>0.05) (Figure 15, Table 5).
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Figure 15. Blood Glucose After Vehicle/Drug Delivery.
Table 5. Blood Glucose RM Two-Way ANOVA. p-values are represented.
Time point
Time point

0.199 Treatment

Treatment

0.54

0.647

Behavioral Assessment
Ladder Walk 24 hours Post-Reperfusion
Number of slips taken across three trials on the ladder rung walk were quantified. No
statistical significance was found between treatment groups at baseline (Mann-Whitney,
p>0.05). A significant reduction in slips occurred in the ST-115 group compared to controls
(Mann-Whitney, p<0.05) (Figure 16). Ladder walk values at 24 hours post-reperfusion were
additionally compared to baseline values by subtracting baseline slips from slips measured at 24
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hours post-reperfusion for each rat (Figure 16). A statistical difference was not found with this
measurement (Mann-Whitney, p>0.05). Degree of protection by ST-115 for both methods of
comparison was 38%.

Figure 16. Horizontal Ladder Rung Walk 24 Hours Post-Reperfusion. (A) # slips/10 steps for
both treatment groups at both time points. (B) # slips/10 steps with baseline values subtracted
from post-stroke. Bars represent medians with interquartile range. * = p<0.05.
Long-Term Ladder Walk
Baseline values between treatment groups were not statistically significant (MannWhitney, p>0.05) (Figure 17). To compare between time points, baseline slips were subtracted
from slips at both 2 weeks and 6 weeks-post reperfusion. No significance was found within or
between treatment groups at both 2 weeks and 6 weeks post-reperfusion (2-way repeated
measures ANOVA, p>0.05) (Figure 17, Table 6). Degree of protection by ST-115 was not
detected at 2 weeks post-reperfusion, however protection at 6 weeks post-reperfusion was
123%.
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Figure 17. Horizontal Ladder Walk 2 and 6 Weeks Post-Reperfusion. (A) Baseline values
between treatment groups for this cohort. (B) # slips/10 steps for both treatment groups at 2
and 6 weeks post-reperfusion. (C) Ladder walk slip pattern for each rat. Bars represent medians
with interquartile range.
Table 6. Long-Term Ladder Walk RM Two-Way ANOVA. p-values are represented.
Time point
Time point

0.485 Treatment

Treatment

0.574

0.47

Immunohistochemistry
Iba1+, CD68+, and Iba1+/CD68+ cells were examined between treatment groups. No
statistical significance was found between treatment groups for levels of Iba1+ cells or ED1+
cells (Mann-Whitney, p>0.05). A significant reduction in cells overlapped with both Iba1 and
Ed1 was detected in ST-115 treated animals (Mann-Whitney, p<0.05) (Figure 18).
Representative images are included in Figure 19.
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Figure 18. Immunohistochemistry 6 Weeks Post-Reperfusion. (A) Schematic illustrating
perilesional and contralateral areas. Gray area represents the infarct. Red squares represent
where images were taken. (B) Numbers of Iba1+, ED1+, and Iba1+/ED1+ cells, respectively.
Comparisons were made between treatment groups in the perilesional area.
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Figure 19. Immunohistochemistry Representative Images. Representative images of Iba1, ED1,
and DAPI triple labeled fluorescence in the perilesional area and contralateral hemisphere for
vehicle and ST-115 treatment groups. Scale bar: 50µm.
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Figure 20. Iba1/ED1 Cells. Representative high-power image of cells triple-stained with Iba1
(red), ED1 (green), and DAPI (blue). White arrows represent cell stained with both Iba1 and
ED1.

CHAPTER FIVE
DISCUSSION
Summary of Results
Our results show that while infarct volume was not attenuated by ST-115 treatment,
edema was significantly reduced 24 hours after reperfusion when rats were treated with ST115. Furthermore, ST-115 reduced behavioral deficit 24 hours after reperfusion compared to
controls, as measured by the horizontal ladder walk test, although this result was not observed
long-term. However, treatment with ST-115 significantly reduced the presence of activated,
phagocytic microglia in the perilesional area six weeks after stoke, indicating an attenuation of
pro-inflammatory responses by ST-115.
Discussion of Results
Infarct volume was measured at 24 hours post-reperfusion with the use of TTC stain.
Our data show that no significance was found between treatment groups at this time point,
suggesting that ST-115 did not reduce the infarct after 90 minutes of tMCAO. It is well known
that the tMCAO model produces considerable variability in infarct size in multiple rat strains,
which is also seen in our study [29, 70]. Upon viewing the data at 24 hours post-reperfusion, it
appears there are approximately four outliers per group, however these are not statistically
relevant. This pattern of outliers and lack of statistical significance between treatment groups
was additionally seen in measurements of infarct volume six weeks post-reperfusion with the
54
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use of Nissl stain. Michel et al. (2019) suggests that in contrast to apparent outliers, data sets
may take a lognormal distribution, and this should be investigated [63]. Our data shows that
infarct volumes for both treatment groups do indeed appear to fit more of a lognormal
distribution, aligning with this proposal. There are multiple mechanisms and pathways
underlying ischemic and reperfusion injury, as explained in depth previously. It is possible that
some pathways may elicit injury in more of a logarithmic matter as opposed to a linear pattern.
A considerable future direction for tMCAO studies is to evaluate multiple markers of ischemic
and reperfusion injury, to determine if larger infarcts are more consistent with some areas of
injury over others, which could indicate pathways presenting a more logarithmic pattern. These
data could additionally provide insight into why ST-115’s effects are not statistically significant
with respect to infarct volume.
Despite unclear results regarding infarct volume, TTC stain concluded that ST-115
significantly reduced levels of brain edema measured at 24 hours post-reperfusion. Bradykinin
is a potent vasodilator, and increasing levels of circulating bradykinin are correlated with
decreased BBB permeability and thus edema [22]. This is an important finding as it appears to
confirm that despite increasing endogenous levels of bradykinin, ST-115 only increases levels to
those that are neuroprotective, and not high enough for injury. In other to strengthen this
finding, brains from animals not undergoing craniotomy for tMCAO should be compared to
evaluate to what extent ST-115 decreases edema with respect to edema resulting from the
operation.
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Furthermore, preliminary measurements of blood glucose did not find a statistical
difference in levels between treatment groups. Bradykinin is known to play an important role in
glucose metabolism, and increasing levels of bradykinin have been associated with decreasing
concentrations of blood glucose [28]. Although no differences were observed, the data are
considerably variable, and more animals are needed to make a definitive conclusion on ST115’s effects on glucose.
The horizontal ladder rung walk was used to measure stroke-induced behavioral deficits
at multiple time points post-reperfusion. No significant difference between treatment groups at
baseline were detected, however a significant increase in slips were seen at 24 hours postreperfusion for both groups, indicating that the ladder walk is a reliable measurement of motor
deficits resulting from ischemic stroke. When the data is initially compared, ST-115 appears to
significantly reduce deficits 24 hours post-reperfusion. However, when baseline slips were
subtracted from post-stroke to account for individual athletic ability per rat, a significant
difference is no longer observed. This method of analysis produced five negative values
between the two groups, indicating that these rats exhibited less slips post-stroke than at
baseline. There are many external factors that can induce motor deficits on this task, for
example stress exhibited by the rat. In order to further investigate whether ST-115 does in fact
support functional recovery, additional behavioral assessments should be utilized post-stroke.
For example, the skilled reaching task and adhesive removal task are both valid measurements
of ischemic stroke-induced motor and sensorimotor deficits [3, 75]. Both behavioral
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assessments are used in the Kartje lab, and would provide a more in depth analysis into
functional recovery from ST-115 treatment. Furthermore, statistical significance was not
detected at the 2-week or 6-week time points post-reperfusion. Additional cohorts and
behavioral assessments should be added to better evaluate ST-115’s effect on long-term
functional recovery.
Two immunohistochemical stains were used to analyze the immune response in brains 6
weeks post-reperfusion: Iba1, staining both resident and activated microglia and ED1, which
stains for CD68 in macrophages. Furthermore, overlap of Iba1+ and ED1+ cells, indicating
activated microglia with macrophage activity, was assessed. No statistical differences were
detected in levels of Iba1+ or ED1+ cells between treatment groups. However, a significant
reduction in overlap of Iba1+ and ED1+ cells was found in the perilesional area in the ST-115
treated group, indicating reduced amounts of activated, macrophagic microglia. Macrophagic
microglia are a key player of the pro-inflammatory response detected weeks after ischemic and
reperfusion injury. As discussed previously, NO and PGI2 released by the activated bradykinin
B2 receptor inhibit NF-κB. NF-κB is generally associated with the release of proinflammatory
cytokines and leukocyte adhesion molecules during ischemic and reperfusion injury. Our results
support that delivery of ST-115 attenuates this proinflammatory response, as measured by
Iba1+/ED1+ cell overlap, by activating the B2 receptor. Furthermore, while no significant
differences were found in ED1+ cells, there appears to be a reducing trend in the ST-115
treated group. In addition to proinflammatory microglia, ED1+ cells can also indicate
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macrophages present the parenchyma. It is expected that after ischemic and reperfusion injury,
disruption of the integrity of the BBB would be associated with higher levels of infiltrating
macrophages entering from the bloodstream. Activation of the B2 receptor has been previously
associated with preservation of BBB permeability [78]. While no statistical significance was
found, more cohorts should be added to this study to investigate this trend in data and
determine if ST-115 is preventing infiltration of circulating macrophages by protecting the BBB.
Despite the lack of statistical significance in analyses of both infarct volume and longterm behavioral deficit, ST-115 may still have a treatment effect. Given the urgent need for a
drug that improves stroke outcomes, distribution and patterns of the data should be taken into
account in addition to the commonly employed accept/reject approach, which is exhibited by
student’s t-tests and Mann-Whitney [40]. Our study incorporates this approach by plotting each
data point when evaluating our results. Furthermore, we evaluated the effect of ST-115 by
calculating degree of protection for each method. ST-115 was shown to have a 46% and 49%
decrease in medians for infarct volumes 24 hours and 6 weeks post-reperfusion, respectively.
Furthermore, ST-115 was calculated to only have a 38% decrease in medians for behavioral
deficits measured at 24 weeks post-reperfusion. However, this increased to a 123% decrease
for deficits measured at 6 weeks. While a conclusive statement cannot be made from these
protection levels due to lack of significance, they provide a basis for future direction. For
example, an anti-inflammatory should be tested in combination with ST-115 to evaluate if the
protection with respect to infarct size could potentially increase. Furthermore, additional
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cohorts should be added to the long-term behavioral assessment studies to strengthen the
conclusion made from the observed 123% decrease.
Future Directions
While this study produced promising results, there are multiple future directions that
should be taken into consideration. First, at 24 hours post-reperfusion, both a reduction in
edema and behavioral deficits were observed in treated rats, however infarct volume was not
statistically different, indicating that edema may be associated with behavioral deficits poststroke. Furthermore, although a change in behavioral deficits was not seen at 6 weeks postreperfusion, decreased levels of phagocytic microglia were detected in treated rats, suggesting
reduced proinflammatory responses. Because increased activation of the bradykinin B2
receptor is associated with reduced inflammation, future ST-115 studies should take a more
detailed look into the relationship between inflammation and behavioral effects. For example,
inflammatory markers should be measured at additional time points (both short and longterm), and additional behavioral assessments should be adapted. It appears from the results
that ST-115 does not exert its effects with respect to reducing infarct volume, but rather
through downstream inflammatory protection that may be further mediating functional
outcomes. It is possible that inflammation present in vehicle-treated groups is significantly
altering the function of neurons, but not to the point of cell death. It could then be proposed
that ST-115 blocks this deleterious cascade, as evidenced by the promising behavioral and
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inflammatory results, and by the lack of changes in infarct volume. This potential mechanism
should be investigated in order to increase the confidence of ST-115’s clinical efficacy.
Next, additional cohorts should be added to studies of ST-115 in order to increase
power. Power analysis assuming a significance of p = 0.05, a Cohen effect size of 0.2 (small
effect) and effect size within one standard deviation reveals that n=15 for each treatment
group is necessary. Additional cohorts would also provide the opportunity to further investigate
the trends seen in the preliminary long-term study of this thesis. Additionally, while
approximately 15% of ischemic stroke victims are adolescents and young adults, the majority of
ischemic stroke victims are older adults [86]. Because of this, ST-115 studies need to be
repeated using aged rats in order to further support the clinical efficacy of this therapeutic
treatment. Furthermore, aged females should be added to the ST-115 studies. While young
men are 33% more likely to be affected by stroke than young women, this statistic is essentially
reversed. Not only are elderly women more likely than elderly men to be victims of stroke, but
these strokes are also more severe, associated with poorer recovery, and induce greater longterm disability than age-matched men. While the mechanisms underlying this phenomenon are
not entirely clear (e.g. decreased estrogen in females, decreased androgens in males, genetic
sex differences, etc.) the sex differences nonetheless need addressed in stroke research,
including in ST-115 studies [49]. Even more, aged stroke victims often present with
comorbidities. One notable comorbidity that should be taken into account is diabetes. Multiple
studies have investigated the roles of the bradykinin B1 and B2 receptors in diabetic vs.
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nondiabetic rats. Not only has B1 hyperactivity been shown to be detrimental in diabetic rats,
but B2 activity has been shown to promote more long-term recovery [78, 81]. Given that the
mechanism of ST-115 indirectly stimulates the activity of the B2 receptor, future ST-115 studies
should include the use of aged, diabetic rats to strengthen its clinical significance.
Conclusion
Figure 2 details the complex interconnected mechanisms that underlie both ischemic
and reperfusion injury. ST-115 delivery blocks the degradation of bradykinin by inhibiting
aminopeptidase P2, endogenously raising bradykinin levels. When ST-115 is given five minutes
prior to reperfusion after ischemic blockage of cerebral arteries, resulting bradykinin levels
activate the upregulated bradykinin B2 receptor, which then initiates the release of small, but
neuroprotective amounts of NO and PGI2. As a result, intracellular Ca2+ stores are released,
strongly reducing downstream cytotoxic edema and excitotoxicity. Reduction of Ca 2+ from
cytotoxic levels then inhibits opening of the MPTP and therefore the induction of apoptosis.
Furthermore, ST-115 blocks the adhesive properties of leukocytes, attenuating the immune
response and therefore reducing the release of proinflammatory cytokines. This then blocks
MMP activation, strengthens BBB integrity, and prevents the capillary no reflow phenomenon.
Further release of proinflammatory cytokines induced by these deleterious mechanisms is
blocked, further attenuating this integrated damaging cascade (Figure 20). Administration of
ST-115 essentially blocks reperfusion injury, resulting in reduced functional decline and
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inflammatory responses as evidenced in this study. Therefore, it is suggested that inhibition of
aminopeptidase P2 by ST-115 is a viable pharmaceutical target for improving stroke outcomes.

Figure 21. Effects of ST-115 on Reperfusion Injury. ST-115 induces release of intracellular Ca2+
stores, reducing cytotoxic edema, excitotoxicity, and opening of MPTPs. ST-115 also helps
prevent leukocyte adhesion, dramatically decreasing release of proinflammatory cytokines. In
the complex cascade of reperfusion injury, this inhibits MMP activation, BBB breakdown,
capillary reflow, additional ROS production, and further MPTP opening. Red X’s represent initial
responses of ST-115, while orange X’s represent downstream effects.
Significance
Use of FDA-approved rtPA treatments and thrombectomy procedures for the prompt
restoration of blood flow following ischemic stroke strongly activate the reperfusion injury
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cascade, worsening damage already elicited by ischemia. Stroke survival and long-term
disability rates are dismal, and there is an urgent need for a pharmaceutical treatment to
attenuate this worsening injury. We show here that ST-115 significantly reduces inflammation
and behavioral deficits. ST-115 is designed to be given just prior, but in combination with rtPA
and/or mechanical thrombectomy, increasing their success in clinic and promoting ischemic
stroke survival and much better outcomes.
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